Voyager Therapeutics, Inc.
VYGR
$3.47
-$0.06-1.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -281.32% | 10.82% | 10.49% | -120.09% | 317.73% |
| Total Depreciation and Amortization | -10.69% | -18.68% | 16.39% | -10.41% | 41.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.25% | -65.86% | 169.31% | 32.27% | 17.98% |
| Change in Net Operating Assets | 177.20% | 21.13% | -140.79% | 181.18% | -3,040.53% |
| Cash from Operations | 48.05% | 11.44% | -153.74% | 347.34% | -12.87% |
| Capital Expenditure | 39.92% | 73.32% | 54.83% | -183.58% | 3.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -141.86% | 284.73% | 62.76% | -440.45% | 117.51% |
| Cash from Investing | -142.27% | 279.04% | 62.58% | -458.01% | 116.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,000.00% | -97.55% | -99.49% | 24,433.91% | 38.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,000.00% | -97.55% | -99.49% | 24,433.91% | 38.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -213.08% | 154.36% | -188.61% | 2,038.64% | 101.97% |